Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/10/2020
SIETES contiene 93130 citas

 
 
 1 a 16 de 16 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart 2019:15 de abril. [Ref.ID 103087]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017;6:6 de junio. [Ref.ID 101674]
3. Cita con resumen
van den Bemt BJF, den Broeder AA, Wolbink G-J, van den Maas A, Hekster YA, van Riel PLCM, Benraad HB, van den hoogen FHJ. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol 2013;76:939-45. [Ref.ID 96632]
4.Tiene citas relacionadas
van der Meer AJ, Hansen BE, Janssen HL. Sustained virological response to treatment in patients with chronic hepatitis C - Reply. JAMA 2013;309:1457. [Ref.ID 95266]
5.Tiene citas relacionadas
Maisonneuve P, Bruno S. Sustained virological response to treatment in patients with chronic hepatitis C. JAMA 2013;309:1457. [Ref.ID 95265]
6. Cita con resumen
Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJV. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. JACC. Heart fail 2013;1:21-8. [Ref.ID 94659]
7.Tiene citas relacionadas Cita con resumen
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, Duarte-Rojo A, Heathcote J, Manns MP, Kuske L, Zeuzem S, Hofmann P, de Knegt RJ, Hansen BE, Janssen HL. Association betweeen sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93. [Ref.ID 94275]
8.
Re III VL, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 2011;155:353-60. [Ref.ID 91503]
9.
Senn S. Individual response to treatment: is it a valid assumption?. BMJ 2004;329:966-8. [Ref.ID 71706]
10. Cita con resumen
Daneshtalab N, Lewanczuk RZ, Russell A, Jamali F. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan. J Clin Pharmacol 2004;44:245-52. [Ref.ID 69282]
11. Cita con resumen
Wandinger KP, Lünemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, Grundström E, Ehrlich S, Wernecke KD, Volk HD, Zipp F. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003;361:2036-43. [Ref.ID 66108]
12.Tiene citas relacionadas
Pedley T A, Hirano M. Is refractory epilepsy due to genetically determined resistance to antiepileptic drugs?. N Engl J Med 2003;348:1480-2. [Ref.ID 65678]
13.Tiene citas relacionadas
Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8. [Ref.ID 65675]
14.
Martínez Pérez JA, Gascueña Luengo M, Sabrozo Alcazar C, Caballero Moreno L, García Pasan MJ, Belmonte Santamaría JEB. Immunoresponse to routine hepatitis B vaccination in pre-adolescents in the province of Guadalajara, Spain. Eur J Public Health 2000;10:168-70. [Ref.ID 52916]
15.
Schumacher J, Schulze TG, Wienker TF, Rietschel M, Nöthen M M. Pharmacogenetics of clozapine response. Lancet 2000;356:506-7. [Ref.ID 52334]
Seleccionar todas
 
 1 a 16 de 16